




Forward-looking statements

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on expectations and assumptions that we believe to be reasonable when made, but that may not prove to be accurate. By their nature, forward-looking statements involve risk and uncertainty. Consequently, the company cannot guarantee their accuracy and their completeness, and actual results may differ materially from those the company anticipated due to a number of uncertainties, many of which the company is not aware of.

For additional information concerning important factors that may cause the company's actual results to differ materially from expectations and underlying assumptions, please refer to the reports filed by the company with the Autorité des Marchés Financiers.

Any forward-looking statement speaks only as of the date on which it is made, and we assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required by law.




CEGEDIM FY Year Earnings 2022



Jean-Claude Labrune

Chairman & CEO



Business Group review



Laurent Labrune

Managing Director



Key Figures 2022

Revenue

€555.2 m

+5.8% Reported

+5.0% Lfl

Recurring
Operating
Income
€25.7m
(36)% €(14.2)m

Net Debt €137m (17)% | €(28)m

Employees 6 073

+8% +430





Cegedim: A strong European presence







Leading integrated player in healthcare, with an unique ecosystem





Breakdown of business by activity



Software & services

55% +3.4%

Cegedim Santé – solutions for HCP in France including Maiia HCP booking platform

CHS – Solutions for HCP in Europe

Smart RX – Solutions for pharmacists in France

Cegedim Insurance – Solutions for Health Insurers

Cegedim SRH – HCM Suite



BPO

Cetip iGestion – BPO for Health insurance companies, claim processing and provident scheme.

Cegedim SRH – BPO HR departments in France



16% +7.5%

Cegedim e-business - Digitalization of contract to pay process. All sectors in France, the UK, and Germany

Cetip Tiers Payant – third party payment management in France



Data & Marketing

19% +8.6%

Cegedim Health Data: Real World database (France, the UK, Romania, Spain, Italy, Belgium and Germany) and Sales Audit

Digital and print marketing at pharmacies in France







SEGUR de la Santé

Physicians Wave 1

Pharmacists Wave 1

28/04/2023 => Postponed 09/20/2023*

End of Wave 1 program
Deployment deadline postponed

Deployment

- > 100% of our softwares LGC / LGO certified
- > Order signature rate nearly 90%

- > Prepayment of 30% on order
- ➤ Remaining 70% on deployment/usage
 - €650 Excl. VAT per Pharmacist in avg
 - €358,33 Excl. VAT per Physician

03/31/2023

Wave 2 Referential publication and associated financing in 2024/2025*

Physicians
Wave 2
Forecast

PARAMED Wave 1

Concertation

« Heart » Wave topics : consolidation wave 1 (DMP, MSS v2, security)

Schedule in 2024 et financing remaining to be discussed

Wave 1 base program services : INS, DMP, MSS.. Physio et Nurses

To be confirmed

9





Cegedim Santé

KPI 2022



MARKET PHYSICIAN

+3.500 PS (+13%)

PMS Appoint./ TLC Physicians + 1.900 PS



4 M patients accounts 31 M appoint. 2.2% not fulfilled





MARKET PARAMEDICQS

+6.600 PS (+15%)



3 600 users 1,5M exchanged messages

Practice Management Software



Physicians +1.200 PS















Cegedim Santé & Smart RX





2022

- + 19% in H2 2022
- Significant recruitment efforts to boost sales and accelerate progress on the product roadmap
- Major investments for the first 'wave' of Ségur health plan
- Maiia Connect and Maiia Kiné have been successful
- Solid position in the multidisciplinary health center and clinic segments
- Reserved capital increase: Malakoff Humanis, VYV and PRO BTP.
- Acquisition of MesDocteurs: Telemedecine 24/7

2023

- Double-digit growth
- Ségur health plan: Finish roll-out of the first 'wave' for doctors, prepare for first 'wave' for paramedicals.
- Maiia services available in the investors members' portals
- Improved profitability and a return to breakeven by end-2024 (positive EBITDA from 2023)



2022

- Stable revenues
- Additional services: Mobile sales (+400 lic.), 4G Pharma (+870 lic.), logistics app (+1,600 lic.), 360G
- -SmartRX NeV launch, 10% of installed base at end-2022
- Major Ségur health plan investments (accredited in Feb. 23)


2023

- Continue migrating installed base to SmartRX NeV
- -Ségur health plan roll-out
- Continue to sell additional services and Business Intelligence 360 Groupement.
- Slight revenue growth





International activities





2022

- UK doctors (InPS):
 - RFP delayed in England
 - Product development continues (NHS regulations)
 - Solid positions in Scotland, Wales, and Northern Ireland
- UK pharmacies (CRX): Restructuring plan following loss of Boots as a client, new sales push

Product of The Year!

 Innovation: Development of next gen webbased software for doctors (SaaS) in Belgium and Romania

2023


- UK doctors:
 - Growth in Scotland
 - Start of production for Ministry Of Defence (MOD)
 - Return to growth and cost containment plan
- UK pharmacies: Sales push (Allcures contract, 45 sites) and cost containment, back to breakeven in 2024
- Launch of next gen web-based software for doctors in Belgium in Q2 and Romania in Q4







Other software businesses, France



Cegedim Insurance Solutions



2022

- 23 million beneficiaries in France managed using our solutions
- Beyond (Next Gen): 3 roll-outs underway, incl. first 2 broker clients
- First sales of fraud detection products (Shift partnership)
- Price increases limited by government-imposed caps



2023

- Business stable to slightly up
- Software installation projects for major players (MGEN, MNH, UNEO, Allianz – Via BPO)
- Continued R&D investment in Beyond and EasyCollectif










Other software businesses, France







2022

- 55 new clients in 2022
- 575k payslips managed (+61k vs 2021)
- More than 1,000 employees at 11 sites
- Expanded range of functions covered
- Laponi acquisition: Absenteeism management

2023

- Double-digit growth
- Continue to win over large clients
- Large start-up projects lay the groundwork for double-digit growth over the medium term
- Companies that integrate and distribute
 Teams RH are ramping up
- Inroads into the public sector market













14













Flow





Cegedim e-business (SY) - 2022

- Double-digit growth (France and Inter).
- Order intake growth (> 2021).
- 177 new clients





- On track to be a partner platform
- Sedia acquisition enhances Hospitalis offering for medical devices
- Sales momentum at international level

Cegedim e-business (SY) - 2023

- New budget / partner platform bills: Pilot programs to start in January 2024
- ISO 27001, SecNumCloud certifications
- Double-digit growth
- Delivery of orders received in 2022
- Convergence of R&D for FR/inter. solutions



2022

- First third-party payment clients for TP Santé
- Partner platform status achieved
- Ramping up in hospitals and progress on ROC projects
- Pharmacy flows back to normal (pre-Covid level)

2023

- Continue roll-out of TP Santé
- Roll out new offerings to our clients (fraud protection, alternative medicine)
- Significant efforts targeting the hospital segment and ROC

 MNH Allianz (1)







Data & Marketing







2022

- Market experiencing strong growth in Europe RWD secondary use value: from €25bn in 2020 to €43bn in 2028 according to European Commission
- THIN: #1 European RWD outpatient database covering 7 countries (+2 in 2022 Germany & Italy). + than 2,000 academic articles
- Clinityx acquisition (health data warehouse)
- GERS added 30 clients vs 2021

2023

- First clients in Germany
- THIN expanded to include RWD from hospitals in France, Italy, and Spain
- Oncology planned for late 2023
- Magellan (Clinityx): 1st and only warehouse of health data extracted from the SNDS (French admin. healthcare database, data covers entire FR population over 5 years) to be authorized by the CNIL (data protection authority)



2022

- Partnerships with pharmacy consortiums strengthened
- Best-ever performance (catching up post Covid).
- Transition to digital (50/50 vs print)

2023

- Innovation in 2023: Carrousels LED, ledigital columns, digital endcaps
- Continued shift to digital







BPO





2022

- New contracts put Cegedim in a leadership position

Allianz





High-profile clients in overflow

- Proven quality (SLA)
- Automation and cost containment

2023

- Allianz, on track for April 1
- Heavy investment to get Allianz contract up and running
- Add functionalities for group personal protection policies
- Ongoing nearshore development in Romania



2022

- 7 new Payroll BPO clients in 2022
- 66k payslips managed
- >230 account managers at 3 sites (FR & RO)

2023

- Double-digit growth
- Continue to target large corporate clients
- Teams Expert Solution dedicated to CPAs

Johnson Johnson








Cegedim is confident in its future growth potential







Finance



Pierre Marucchi

Managing Director



The big picture

Revenue €555.2 m

+ €30.5 m

+5.8% +5.0% Reported Lfl

EBITDA

€96.2 m

(8)% €(8.5)m

Exceptional items

€0.8 m €3.8 m

2022 2021

Net Profit

€12.1 m

(54)% €(14.2) m

Operating FCF

€86.5 m

(9,9)% €(9.5)m

Net debt

Excl. IFRS 16

€137.2 m

(17)% €(28)m





Acquisitions 2022

Mesdocteurs | May 2022

A leader in telehealth and a pioneer in 24/7 telemedicine

SEDIA | July 2022

Tracking software for medical instrumentation since 1985

Laponi | June 2022

An SaaS innovative solution for managing absenteeism in real time

Clinityx | July 2022

Innovative data valorization model with Real world data and matching expertise





FY 2022 P&L


In € million	2022	2021	Var %	Var. €m
Revenue	555.2	524.7	5.8 %	30.5
Purchase used	(26.6)	(26.7)	(0.5) %	0.1
External expenses	(119.9)	(107.4)	11.6 %	(12.5)
Employee costs	(303.6)	(278.8)	8.9 %	(24.7)
Others	(9.0)	(7.1)	27.0 %	(1.9)
EBITDA	96.2	104.7	(8.1) %	(8.5)
Margin EBITDA	17.3%	20.0%		
D&A	(70.6)	(64.8)	8.8 %	5.7
Recurring operating income	25.7	39.9	(35.7)%	(14.2)
Margin ROC	4.6%	7.6%		
Non-recurring operating income and expenses	0.8	3.8	n.m.	(3.0)
Operating income	26.5	43.7	(39.4)%	(17.2)
Financial results	(8.8)	(10.4)	(15.2)%	+1.6
Total Tax	(4.6)	(5.8)	(21.0)%	+1.2
Share of profit (loss)for the period of equity method companies	(1.0)	(1.2)	(14.0)%	0.2
Consolidated net profit	12.1	26.3	(54.1)%	(14.2)






Payroll costs


Payroll costs



Headcount




Offshore








R&D Investistment





Impact on recurring operating income

Capitalized R&D €5.0m

D&A of R&D €(4.3)m

impact on recurring operating income

*Excluding non recurring D&A





Free cash flow

In € million	2022	2021	
Consolidated net profit	12.1	26.3	Net Debt
Depreciation and amortization expenses and provisions Cost of net financial debt	83.1 8.8	64.4 10.4	2021
Share of earnings from equity method companies ; tax expenses	3.3	4.0	
Operating Cash flow before cost of net financial debt and taxes	107.3	105.2	€165m
Tax paid Change in working capital requirements from operations	(21.3) +0.5	(4.1) (5.1)	
Cash flow generated from operating activities (A)	86.5	96.0	
Acquisition of intangible assets	(58.6)	(50.7)	
Acquisition of tangible assets	(17.6)	(14.0)	
Impact of changes in consolidation scope Others	+52.5 +3.5	(5.1) (0.2)	2022
Net Cash flow generated by investment operations (B)	(20.2)	(70.1)	
Repayment of lease liabilities	(19.0)	(16.8)	
Dividends Others	(6.9) (8.0)	0 (9.9)	€ 137m
Net cash flow generated by financing operations (C)	(33.9)	(26.7)	
Change in cash (A+B+C)	+32.4	(0.9)	



© Cegeaim zuz3 25



Financing

Principal financing

	Status	Amount	Maturity
Euro PP	-	€135.0m	October 2025
Shareholder lan	-	€45.1m	November 2025
RCF	Undrawn	€ 65.0m	October 2024
Overdraft	Unused	€24.0m	-
Cash & cash equivalents	-	€24.2m	-

Debt Covenant

	Status	Limit
Leverage (Debt/Ebitda)	1.09	< 2.50
Interest cover (Ebitda/ interest debt)	14.68	> 4.50

31 Décembre 2022

31 Décembre 2022





Sound financial structure

Assets

In € million	2022	2021
Goodwill	198.8	187.1
Intangible assets	188.1	179.9
Tangible assets	131.0	121.7
Financial assets	20.7	21.3
Oher non-current assets	51.0	54.9
Cash & cash equivalents	55.6	24.2
Trade receivables, short-term portion	151.8	136.3
Other current assets	93.1	72.2
Total assets	889.9	797.6

Shareholders equity & liabilities

In € million	2022	2021
Shareholder equity	304.1	232.4
Long-term financial debt	188.9	186.6
Other non-current liabilities	109.8	114.9
Short-term financial debt	3.9	2.6
Other current liabilities	283.2	261.2
Total equity and liabilities	889.9	797.6



55% of 2022 Group revenue €302.0m +3.4% Revenue

€(4.9)m €(17.7)m Recurring Operating Income

	Rev	enue		2022 / 021	Recu Oper Inco			2022 / 021
In € million	2022	2021	€m	%	2022	2021	€m	%
Total Softwares et Services	302.0	292.0	10.0	3.4%	(4.9)	12.8	(17.7)	(138)%
Cegedim Santé	69.6	63.1	6.5	10.3%	(7.8)	2.2	(9.9)	(457.2)%
Insurance, HR, Pharmacists and others services	183.5	175.0	8.5	4.8%	14.3	14.0	0.3	1.9%
International Activities	48.9	53.9	(5.0)	(9.3)%	(11.4)	(3.3)	(8.0)	(241.1)%



28



16% of 2022 Groupe revenue €90.6m Revenue

+7.5 % **€13.1m** +17.6 % Recurring Operating Income

	Rev	enue	Var. 202	22 / 2021	Recur Oper Inco	ating	Var. 20	22 / 2021
In € million	2022	2021	€m	%	2022	2021	€m	%
Total Flow	90.6	84.2	+6.4	+7.5%				
e-business	53.9	48.7	+5.2	+10.6%	13.1	11.1	+2.0	+17.6%
Tiers Payant	36.7	35.5	+1.2	+3.3%				



19% of 2022 Groupe revenue Revenue

€106.9m +8.6% €17.4m +22.9% +€8.5m Recurring Operating Income

	Rev	enue	Var. 2022 / 2021		
In € million	2022	2021	€m	%	
Total Data & Marketing	106.9	98.4	+8.5	+8.6%	
Data	61.4	56.8	+4.5	+7.9%	
Marketing	45.5	41.6	+4.0	+9.5%	

Recu Oper Inco	ating	Var. 20	22 / 2021
2022	2021	€m	%
17.9	14.6	+3.3	+22.9%



10% of 2022 Groupe Revenue

€53.0m +11.9% Revenue +€5.7m

€3.0m +20.7%
Recurring Operating Income


	Revenue		Var. 2022 / 2021		
In € million	2022	2021	€m	%	
Total BPO	53.0	47.3	+5.7	11.9%	
BPO Insurance	32.1	29.2	+2.9	10.1%	
BPO HR	20.8	18.1	+2.7	14.9%	

Recur Oper Inco	ating	Var. 20	22 / 2021
2022	2021	€m	%
3.0	2.5	+0.5	+20.7%





CSR Challenge



2022

- External Rating
- Program Green IT
- Energy sobriety plan
- Taxonomie alligned activities

2023

- Complete Carbon footprint assesment Sustainable net zero path
- Labeling ISO 26000 RSE engaged Social responsibility
- Certifications ISO 50001 Energy Management and ISO 14001 - Environmental Management
- Climate risks analysis
- Corpus of sustainabily politics : Environment. HR, Purchase, Ethic, Stakeholders





CSR - External Rating

Provider





Ecovadis



Silver medal 70% percentile top 19% of the evaluated companies



Gaïa



Bronze medal



Vigeo Eiris



52/100



CDP



Note D (Incomplete data)



Score carbone Axylia



Rate A



Label Engagé RSE



A venir (note sur 1000)

33





Outlook 2023




Revenue

expects 2023 likefor-like growth to be around 10%



Recurring
Operating Income

Increase



The Group does not expect to make any significant acquisitions in 2023. And lastly, the Group does not provide earnings estimates or forecasts.





2023 Financial agenda

Avril 27

After the market closes

Q1 Revenue

2023

June 16

Shareholder's meeting

2023

July 27

After the market closes

H1 Revenues

2023


September 20

After the market closes

H1 Earnings

2023





Q&A session




Jean-Claude Labrune



Laurent Labrune



Pierre Marucchi



Thank you for your attention

For any additional information:

Erome.moreau@cegedim.com

www.cegedim.com/finance

Download our mobile app Cegedim IR in iOS and Android and follow us on









